36187-69-6

Usage

Uses

Used in Pharmaceutical and Agrochemical Industries:
Ethyl 4-bromo-3-oxopentanoate is used as a key intermediate in the synthesis of various pharmaceuticals and agrochemicals, contributing to the development of new drugs and pesticides. Its role in these industries is crucial for the creation of effective and innovative products.
Used in Organic Synthesis:
As a building block, Ethyl 4-bromo-3-oxopentanoate is used in the preparation of a wide range of organic compounds, including esters and carboxylic acids. Its structural properties make it a versatile component in organic chemistry, facilitating the synthesis of complex molecules.
Used in Perfumery and Flavoring Industry:
Ethyl 4-bromo-3-oxopentanoate is utilized in the production of perfumes and flavoring agents, where its slightly fruity odor is harnessed to create desirable scents and tastes in consumer products. Its application in these industries adds to the sensory experience of various goods, enhancing their appeal to consumers.

InChI:InChI=1/C7H11BrO3/c1-3-11-7(10)4-6(9)5(2)8/h5H,3-4H2,1-2H3

Upstream product

• 4949-44-4 ethyl propanoylacetate 
• 141-78-6 ethyl acetate 
• 7148-74-5 2-Bromopropionyl chloride 
• 4111-54-0 lithium diisopropyl amide 

Downstream Products

• 152645-35-7 4,5-Dihydro-5-methyl-2-<(2-nitrophenyl)amino>-4-oxo-3-furancarboxylic acid ethyl ester 
• 36904-76-4 (±)-4-hydroxy-5-methylfuran-2(5H)-one 
• 859521-92-9 2-(2-amino-5-methylthiazol-4-yl)acetic acid ethyl ester 
• 175136-30-8 2-[5-methyl-2-phenyl-1,3-thiazol-4-yl]ethanol 
• 6179-14-2 2,5-dimethylbenzo[b]thiophene-3-acetic acid 
• 866534-33-0 [5-methyl-2-(4-trifluoromethyl-phenyl)-thiazol-4-yl]-acetic acid ethyl ester 
• 115320-89-3 4,5-dihydro-5-methyl-4-oxo-2-(phenylamino)-3-furancarboxylic acid 
• 679834-90-3 (2S)-2-[(2-benzoylphenyl)amino]-3-(4-{2-[2-(3-{3-[(tert-butoxycarbonyl)amino]-1-propynyl}phenyl)-5-methyl-1,3-oxazol-4-yl]ethoxy}phenyl)propanoic acid 
• 679834-89-0 methyl (2S)-2-[(2-benzoylphenyl)amino]-3-(4-{2-[2-(3-{3-[(tert-butoxycarbonyl)amino]-1-propynyl}phenyl)-5-methyl-1,3-oxazol-4-yl]ethoxy}phenyl)propanoate 
• 679834-87-8 methyl (2S)-2-[(2-benzoylphenyl)amino]-3-(4-{2-[2-(3-iodophenyl)-5-methyl-1,3-oxazol-4-yl]ethoxy}phenyl)propanoate 
• 679834-86-7 2-[2-(3-iodophenyl)-5-methyl-1,3-oxazol-4-yl]ethanol 
• 679834-85-6 ethyl [2-(3-iodophenyl)-5-methyl-1,3-oxazol-4-yl]acetate 

Relevant academic research and scientific papers

β-LACTAM COMPOUNDS, THEIR PREPARATION AND USE AS ANTIBACTERIAL AGENTS

Provided are β-lactam compounds of formula (I), their preparation and use as antibiotic agents for the treatment of bacterial infections: Wherein X, W, R 1, R 2 and R 3 are defined herein.

Synthesis and Antibacterial Activities of Amidine Substituted Monocyclic β-Lactams

Background: Mononcyclic β-lactams are regarded as the most resistant class of β-lactams against a series of β-lactamases, although they possess limited antibacterial activity. Aztreonam, being the first clinically approved monobactam, needs broad-spectrum efficacy through structural modification. Objective: We strive to synthesize a number of monocyclic β-lactams by varying the substituents at N1, C3, and C4 positions of azetidinone ring and study the antimicrobial effect on variable bacterial strains. Methods: Seven new monobactam derivatives 23a-g, containing substituted-amidine moieties linked to the azetidinone ring via thiazole linker, were synthesized through multistep synthesis. The final compounds were investigated for their in vitro antibacterial activities using the broth microdilution method against ten bacterial strains of clinical interest. The minimum inhibitory concentrations (MICs) of newly synthesized derivatives were compared with aztreonam, ceftazidime, and mero-penem, existing clinical antibiotics. Results: All compounds 23a-g showed higher antibacterial activities (MIC 0.25 μg/mL to 64 μg/mL) against tested strains as compared to aztreonam (MIC 16 μg/mL to >64 μg/mL) and ceftazidime (MIC >64 μg/mL). However, all compounds, except 23d, exhibited lower antibacterial activity against all tested bacterial strains compared to meropenem. Conclusion: Compound 23d showed comparable or improved antibacterial activity (MIC 0.25 μg/mL to 2 μg/mL) to meropenem (MIC 1 μg/mL to 2 μg/mL) in the case of seven bacterial species. Therefore, compound 23d may be a valuable lead target for further investigations against multi-drug resistant Gram-negative bacteria.

Cephalosporin drug intermediate and synthesis method thereof

The invention provides a cephalosporin drug intermediate and a synthesis method thereof, and belongs to the technical field of medicine synthesis. The synthesis method comprises the following steps: d) reacting a compound with a structure as shown in a formula (IV) with stannic oxide to obtain a compound with a structure as shown in a formula (V-1); and e) reacting the compound with the structureas shown in the formula (V-1) with sodium hydroxide to obtain a compound with a structure as shown in a formula (V-2); and according to the synthetic method of the cephalosporin drug intermediate provided by the invention, the obtained cephalosporin drug intermediate can be used as a cephalosporin antibiotic intermediate for preparing cephalosporin antibiotics. The method has the advantages of wide raw material sources, reasonable reaction route, mild reaction conditions and high product yield, and is suitable for large-scale production.

Low-Temperature Reactions of α-Bromopropanoyl Chloride with Lithium Derivative of Ethyl Acetate

The reaction of 2-bromopropanoyl chloride with lithium ethyl acetate generated in situ by the reaction of equimolar amounts of lithium diisopropylamide with ethyl acetate forms, depending on the conditions (temperature, time, reagent ratio), diethyl 2,2′-(3-methyloxirane-2,2-diyl)diacetate, 2,2-dibromo-N,N-diisopropylpropanamide, and ethyl (5-methyl-4-oxo-4,5-dihydrofuran-2-yl)acetate as minor by-products along with the expected acylation product ethyl 4-bromo-3-oxopentanoate. The reaction with 2 or 5 equiv of lithium ethyl acetate (–78°C → –20°C) gave, together with the mentioned α-bromo ester, ethyl (5-methyl-4-oxo-4,5-dihydrofuran-2-yl)acetate formed as a result of transformations of the adduct of the second LiCH2CO2Et molecule and ethyl-4-bromo-3-oxopentanoate. The reaction 2-bromopropanoyl chloride with sodium malonic ester involves acylation of enol form of the primary expected acylation product to afford dimethyl |2-bromo-1-[(2-bromopropanoyl)oxy]propylidene-malonate.

SHMT INHIBITORS AND USES THEREOF

The present invention provides compounds, compositions thereof, and methods of using the same.

INHIBITORS OF RENAL OUTER MEDULLARY POTASSIUM CHANNEL

Novel spirocyclic compounds of formula I: and pharmaceutically acceptable salts thereof are disclosed as inhibitors of the ROMK (Kir1.1) channel. The compounds may be used as diuretic and/or natriuretic agents and for the therapy and prophylaxis of medical conditions including cardiovascular diseases such as hypertension, heart failure and chronic kidney disease and conditions associated with excessive salt and water retention. Pharmaceutical compositions and methods of treatment are also included.

INHIBITORS OF THE RENAL OUTER MEDULLARY POTASSIUM CHANNEL

Novel spirocyclic compounds of formula I: and pharmaceutically acceptable salts thereof are disclosed as inhibitors of the ROMK (Kir1.1) channel. The compounds may be used as diuretic and/or natriuretic agents and for the therapy and prophylaxis of medical conditions including cardiovascular diseases such as hypertension, heart failure and chronic kidney disease and conditions associated with excessive salt and water retention. Pharmaceutical compositions and methods of treatment are also included.

INHIBITORS OF THE RENAL OUTER MEDULLARY POTASSIUM CHANNEL

The present invention provides compounds of Formula I and the pharmaceutically acceptable salts thereof, which are inhibitors of the ROMK (Kir1.1) channel. The compounds may be used as diuretic and/or natriuretic agents and for the therapy and prophylaxis of medical conditions including cardiovascular diseases such as hypertension, heart failure and conditions associated with excessive salt and water retention.

SPIRO - FUSED PIPERIDINE DERIVATIVES FOR USE AS INHIBITORS OF THE RENAL OUTER MEDULLARY POTASSIUM CHANNEL

The present invention provides compounds of Formula I and the pharmaceutically acceptable salts thereof, which are inhibitors of the ROMK (Kir1.1) channel. The compounds may be used as diuretic and/or natriuretic agents and for the therapy and prophylaxis of medical conditions including cardiovascular diseases such as hypertension, heart failure and conditions associated with excessive salt and water retention.

INHIBITORS OF THE RENAL OUTER MEDULLARY POTASSIUM CHANNEL

The present invention provides compounds of Formula (I) and the pharmaceutically acceptable salts thereof, which are inhibitors of the ROMK (Kir11) channel. The compounds may be used as diuretic and/or natriuretic agents and for the therapy and prophylaxis of medical conditions including cardiovascular diseases such as hypertension, heart failure and chronic kidney disease and conditions associated with excessive salt and water retention.